TSI Group Co., Ltd. Class A

TSI Group Co., Ltd. Class A

SSSE:603262
14.64
CNY
+0.31
(+2.16%)
0.30EPS
58.33P/E
6.82BMarket Cap
Mar 03Next Earn
TSI Group Co., Ltd. Class A
SSE:603262
(Shanghai Stock Exchange)

Recent

price

14.64

P/E

ratio

58.33

div

yld

0.61%

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.54
1.87
2.41
2.73
2.56
2.87
2.94
2.76
Revenue per Share
0.14
0.12
0.33
0.41
0.46
0.5
0.36
0.29
Basic EPS, GAAP
0.1
0.19
0.06
0.29
0.34
0.34
-0.09
- -
Free Cash Flow per Basic Share
0.02
0.02
0.02
0.04
- -
- -
- -
0.09
Dividend per Share
0.36
0.67
1.2
1.71
2.18
2.68
3.87
3.88
Book Value per Share
0.12
0.43
0.96
1.5
1.98
2.47
3.71
3.67
Tangible Book Value per Share
400
400
333
347
348
349
371
396
Basic Weighted Avg Shares
614
746
801
947
892
1,002
1,093
1,091
Sales/Revenue/Turnover
15.91
11.77
18.2
18.5
20.19
19.84
15.46
15.79
Operating Margin (%)
12
19
24
30
36
44
49
- -
Depreciation Expense
57
47
110
142
160
174
134
116
Net Income, GAAP
16.21
25.68
14.76
14.66
13.09
12.35
11.58
12.82
Effective Tax Rate (%)
9.23
6.28
13.71
15
17.94
17.41
12.23
10.6
Profit Margin (%)
-52
20
141
293
439
569
1,030
948
Working Capital
- -
5
2
3
5
4
25
20
LT Debt
126
235
419
607
771
946
1,559
1,565
Total Equity
- -
14.43
22.65
22.89
20.95
19.61
10.59
8.81
Return on Invested Capital (%)
- -
16.74
23.77
22.85
21.19
19.67
10.44
8.64
Return on Capital (%)
- -
26.47
34.18
28.06
23.48
20.52
10.75
8.93
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
16
17
16
LT Borrowings
- -
- -
- -
LT Finance Leases
25
22
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
400
Market Capitalization
9,896
9,848
6,824

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,187
1,235
1,155
Cash, Cash Equivalents & STI
712
774
709
Accounts Receivable, Net
210
205
206
Inventories
230
222
210
Total Current Liabilities
184
225
207
Payables & Accruals
- -
- -
- -
ST Debt
16
17
16
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.56%
64.82%
Free Cash Flow
- -
37.93%
-129.4%
Net Income, GAAP
- -
32.43%
-23.36%
Sales/Revenue/Turnover
- -
8.24%
9.1%
Total Cash Common Dividend
- -
-21.79%
-54.65%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
227
260
- -
- -
1,002
2025
265
298
- -
296
1,093
2026
240
275
280
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.16
- -
- -
0.5
2025
0.12
0.14
- -
0.04
0.36
2026
0.06
0.13
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
0.09
- -
- -
Business
TSI Group Co., Ltd. engages in the discovery, development, manufacturing, and sale of vitamins and dietary supplements for healthy lifestyles worldwide; it offers vegan glucosamine under the GlucosaGreen brand; ß-hydroxy ß-methylbutyrate under the myHMB brand; adenosine 5’- triphosphate under the PEAK ATP brand for body composition and athletic performance; 2-hydroxybenzylamine to support cellular health; enfinity, a downstream metabolite of caffeine; vitamins and dietary supplements under the FZZR and STRW brands; and glucosamine tablets under the OptiTab brand. The company operates across multiple global markets, with a focus on research and development, formulation, and scalable manufacturing of nutraceuticals and functional ingredients. Headquartered in Shanghai, China, it serves professional distributors, contract manufacturers, and direct-to-consumer channels, and concentrates on expanding its portfolio through targeted partnerships, product line extensions, and strategic collaborations to address growing consumer demand for dietary supplements and wellness solutions. Founded in 201? (founding year referenced in public profiles) and listed on the Shanghai Stock Exchange under ticker 603262.SS, TSI Group maintains a diversified product ecosystem, including branded nutraceuticals and OEM/ODM manufacturing capabilities to support global health and wellness brands. The company prioritizes quality assurance, compliance with international regulatory standards, and end-to-end supply chain integrity to service retailers, e-commerce platforms, and institutional customers across regions. Recent strategic activities include partnerships and potential portfolio expansions to accelerate market penetration in Europe, North America, and Asia, alongside ongoing investment in product innovations and capacity expansion to meet rising demand for scientifically formulated health solutions.